Crizotinib, the first clinically approved drug to target ALK, is a tyrosine kinase inhibitor that was approved for use in echinoderm microtubule-associated protein-like 4 EML4-ALK-positive non-small-cell lung cancer (NSCLC). This evidence concerns the gene ALK and non-small cell lung carcinoma.